Hormones, E.g., Prolactin, Thymosin, Growth Factors, Etc. Patents (Class 530/399)
-
Patent number: 8865122Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.Type: GrantFiled: April 2, 2013Date of Patent: October 21, 2014Assignee: Genentech, Inc.Inventors: Herman Gill, Jan Marik, Jeff Tinianow, Simon Williams
-
Patent number: 8865864Abstract: Compositions that are EGF polypeptides that possess improved biological activity as compared to the biological activity exhibited by wild-type EGF are provided. Also provided are methods for the preparation of these mutants, methods for the use of these mutants, methods for rationally designing new polypeptide mutants, and methods for screening mutants polypeptides to identify novel EGF mutants with desirable biological activities.Type: GrantFiled: August 27, 2012Date of Patent: October 21, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Bertrand Howyen Lui, Jennifer Lynn Lahti, James R. Swartz, Bob Chen, Cheuk Lun Leung
-
Patent number: 8865658Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.Type: GrantFiled: May 9, 2012Date of Patent: October 21, 2014Assignee: AMBRX, Inc.Inventors: Zhenwei Miao, Junjie Liu, Thea Norman
-
Patent number: 8865673Abstract: Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.Type: GrantFiled: September 7, 2012Date of Patent: October 21, 2014Assignee: The General Hospital CorporationInventors: Michael Detmar, Kentaro Kajiya
-
Patent number: 8859724Abstract: The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.Type: GrantFiled: April 26, 2007Date of Patent: October 14, 2014Assignee: B. Braun Melsungen AGInventors: Bernd H. Meier, Nele Meier
-
Patent number: 8859498Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: June 18, 2013Date of Patent: October 14, 2014Assignee: Biomarin Pharmaceutical Inc.Inventors: Jonathan LeBowitz, Stephen M. Beverley
-
Publication number: 20140303078Abstract: Work described herein provides, in one embodiment, a method for increasing proliferation or replication of pancreatic beta cells in a subject in need thereof, comprising administering to said subject an effective amount of an agent that increases the level or activity of hepatocellular carcinoma-associated protein TD26 (TD26), thereby increasing proliferation or replication of pancreatic beta cells. Such an agent may function by, for example, increasing the level of active TD26 in the subject or by increasing the functional activity of TD26 in the subject.Type: ApplicationFiled: June 10, 2012Publication date: October 9, 2014Applicant: President and Fellows of Harvard CollegeInventors: Douglas A. Melton, Peng Yi
-
Publication number: 20140301977Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant by overloading a chromatography material and eluting the product.Type: ApplicationFiled: November 2, 2012Publication date: October 9, 2014Inventors: Deepa Nadarajah, Amit Mehta
-
Publication number: 20140302581Abstract: The present invention provides a method of increasing protein production in a cell culture by growing cells that produce the protein (e.g., the growth phase) in a perfusion cell culture to a high cell density (i.e., at least above about 40×106 cells/mL) and then switching to a protein production phase, wherein the cells are cultured in a fed-batch cell culture. The present invention further provides a method for clarifying a protein from a cell culture by adjusting the pH of the cell culture to below neutral pH (i.e., below a pH of 7) and settling the cell culture, such that the cell culture separates to form a supernatant layer and a cell-bed layer, wherein the protein is in the supernatant layer.Type: ApplicationFiled: June 19, 2014Publication date: October 9, 2014Inventors: Alahari Arunakumari, Xiao-Ping Dai, Javier Garcia, Richard P. Martel
-
Publication number: 20140301974Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.Type: ApplicationFiled: January 30, 2014Publication date: October 9, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
-
Publication number: 20140302001Abstract: Described herein are methods of making targeting peptides conjugated to recombinant lysosomal enzymes by modifying the amino (N)-terminus and one or more lysine residues on recombinant human lysosomal enzymes using a first crosslinking agent to give rise to first crosslinking agent modified recombinant human lysosomal enzymes, modifying the first amino acid within a short linker at the amino (N)-terminus on a variant IGF-2 peptide using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short linker. Also described herein are conjugates synthesized characterized as having higher affinities for the IGF2/CI-MPR receptor and cellular uptake using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.Type: ApplicationFiled: May 25, 2012Publication date: October 9, 2014Applicant: Callidus Biopharma, Inc.Inventor: Hung Do
-
Patent number: 8853163Abstract: The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.Type: GrantFiled: May 21, 2010Date of Patent: October 7, 2014Assignees: Cornell Research Foundation, Inc., Children's Medical Center CorporationInventors: Barbara L. Hempstead, Rosemary Kraemer, Shahin Rafii, Phi Wiegn, Michael J. Donovan
-
Patent number: 8853166Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.Type: GrantFiled: April 30, 2009Date of Patent: October 7, 2014Assignee: Herantis Pharma PLC.Inventors: Mart Saarma, Päivi Lindholm, Merja Voutilainen, Johan Peränen, Raimo Tuominen, Mikko Airavaara, Veli-Matti Leppänen, Maria Lindahl, Jaan-Olle Andressoo
-
Publication number: 20140295521Abstract: A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.Type: ApplicationFiled: January 21, 2014Publication date: October 2, 2014Applicant: AFFIBODY ABInventor: Nina Herne
-
Publication number: 20140294757Abstract: A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide.Type: ApplicationFiled: October 5, 2012Publication date: October 2, 2014Applicant: Stabilitech Ltd.Inventors: Jeffrey Drew, David Thomas Woodward, Stephen Ward
-
Publication number: 20140287996Abstract: The present invention relates to compositions and methods for neuroprotection. In particular, provided herein are compositions (e.g., hepatocyte secretory factors) for alleviating and/or protecting against neuronal damage (e.g., resulting from stroke), and methods of use thereof.Type: ApplicationFiled: June 12, 2014Publication date: September 25, 2014Inventor: Shu Q. Liu
-
Patent number: 8841249Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.Type: GrantFiled: August 6, 2010Date of Patent: September 23, 2014Assignee: Novo Nordisk A/SInventors: Nils Langeland Johansen, Henrik Sune Andersen, Jens Buchardt, Leif Norskov-Lauritsen
-
Patent number: 8841252Abstract: The invention relates to aqueous pharmaceutical formulations comprising human growth hormone, histidine, poloxamer, phenol, and mannitol.Type: GrantFiled: October 8, 2009Date of Patent: September 23, 2014Assignee: Novo Nordisk Health Care AGInventors: Søren Bjørn, Hans Holmegaard Sørensen, Peter Langballe, Silke Møller Larsen, Kristen Ebbehøj, Birthe Lykkegaard Hansen
-
Patent number: 8841426Abstract: Provided are mutants of human granulocyte-colony stimulating factor (G-CSF) designed for specific chemical conjugation, and chemical conjugates thereof for use as an adjuvant in the treatment of cancer. The present invention provides a mutant of a G-CSF in which a threonine (Thr) residue at position 133 of G-CSF comprising the amino acid sequence identified in SEQ ID NO: 1 is substituted with a cysteine (Cys) residue. In addition, the invention provides a mutant of a G-CSF in which a cysteine (Cys) residue is inserted between a glycine (GIy) residue at position 135 and an alanine (Ala) residue at position 136 of G-CSF.Type: GrantFiled: July 19, 2006Date of Patent: September 23, 2014Assignee: Mogam Biotechnology Research InstituteInventors: Kwan-Yub Kang, Jeong-Woon Hong
-
Patent number: 8840886Abstract: The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided.Type: GrantFiled: July 23, 2013Date of Patent: September 23, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Irene Noguera-Troise, Gavin Thurston, Alain Thibault
-
Publication number: 20140271640Abstract: The present disclosure provides complexes comprising an FGF-10 portion and a heterologous protein or peptide, as well as methods of using such complexes.Type: ApplicationFiled: December 6, 2013Publication date: September 18, 2014Applicant: PERMEON BIOLOGICS, INC.Inventors: Katherine S. Bowdish, Erik M. Vogan, John F. Ross, Ann Dewitt
-
Publication number: 20140274894Abstract: Non-centrifugal methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The solution rich in IL-1ra can also include at least one of sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1 RII.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: BIOMET BIOLOGICS, LLCInventors: Michael D. LEACH, Jennifer E. WOODELL-MAY, Joel C. HIGGINS, Krista O'SHAUGHNESSEY
-
Publication number: 20140274898Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.Type: ApplicationFiled: February 20, 2014Publication date: September 18, 2014Applicant: FIVE PRIME THERAPEUTICS, INC.Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
-
Patent number: 8834879Abstract: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.Type: GrantFiled: April 3, 2013Date of Patent: September 16, 2014Assignee: ZymoGenetics, Inc.Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
-
Patent number: 8833306Abstract: The present invention is related to the use of variants of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) to stimulate the growth and to improve the immunological system of aquatic organisms. The variants of the peptide were provided by immersion, injection or as a food additive.Type: GrantFiled: November 20, 2006Date of Patent: September 16, 2014Assignee: Centro de Ingenieria Genetica Y BiotecnologiaInventors: Juana Maria Lugo González, Mario Pablo Estrada Garcia, Alina Rodriguez Mallon, Yamila Carpio González, Antonio Morales Rojas, Osmany Rodrigo González De Sosa, Reynold Morales Fernández, Fidel Francisco Herrera Miyares
-
Patent number: 8835385Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, wherein the FGF 21 mutant polypeptides comprise two or more mutations, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: GrantFiled: March 21, 2012Date of Patent: September 16, 2014Assignee: Amgen Inc.Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
-
Publication number: 20140256621Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: July 3, 2012Publication date: September 11, 2014Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekbland, Jonathan David Roth
-
Publication number: 20140255991Abstract: Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallylglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine.Type: ApplicationFiled: January 9, 2014Publication date: September 11, 2014Applicant: California Institute of TechnologyInventors: David A. Tirrell, Kristi Lynn Kiick
-
Publication number: 20140256917Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).Type: ApplicationFiled: May 27, 2014Publication date: September 11, 2014Applicants: The United States Government as represented by the Department of Veterans Affairs, Loma Linda UniversityInventors: Kin-Hing William Lau, Susan L. Hall, Shin-Tai Chen, Subburaman Mohan, David J. Baylink
-
Patent number: 8829163Abstract: Disclosed is a liquid formulation which allows long-acting EPO conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting EPO conjugates.Type: GrantFiled: January 18, 2011Date of Patent: September 9, 2014Assignee: Hanmi Science Co., LtdInventors: Sung Min Bae, Dae Seong Im, Min Young Kim, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
-
Patent number: 8828941Abstract: The present invention provides compositions of matter suitable for the prevention of and/or treatment of a spinal disorder and/or spinal pain, e.g., caused by and/or associated with intervertebral disc (IVD) degeneration, and methods of treatment of a spinal disorder and/or spinal pain. For example, the compositions of the present invention comprise a modulator of growth differentiation factor (GDF)-6 signaling sufficient to reduce or prevent or delay IVD degeneration and/or to enhance or induce IVD regeneration. The present invention also provides medical devices comprising such compositions, and methods of treatment making use of such compositions.Type: GrantFiled: February 22, 2008Date of Patent: September 9, 2014Inventors: Ashish Diwan, Divya Diwan
-
Publication number: 20140248334Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.Type: ApplicationFiled: February 7, 2014Publication date: September 4, 2014Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
-
Publication number: 20140248302Abstract: A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats.Type: ApplicationFiled: November 21, 2012Publication date: September 4, 2014Applicant: BIOVEN 3 LIMITEDInventors: Keith Alan Charlton, Erik D'Hondt
-
Publication number: 20140249299Abstract: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.Type: ApplicationFiled: March 3, 2014Publication date: September 4, 2014Applicants: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: Odile Esther Levy, Michael R. Hanley, Carolyn M. Jodka, Diana Y. Lewis, Christopher J. Soares, Soumitra S. Ghosh, Lawrence J. D'Souza, David G. Parkes, Christine M. Mack
-
Publication number: 20140243260Abstract: The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule. The present invention also relates to a pharmaceutical composition including an isolated chimeric protein and a pharmaceutically acceptable carrier. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule, and a pharmaceutically-acceptable carrier. Yet another aspect of the present invention relates to a method for treating a subject suffering from a disorder.Type: ApplicationFiled: February 20, 2014Publication date: August 28, 2014Applicant: NEW YORK UNIVERSITYInventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20140235538Abstract: The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.Type: ApplicationFiled: January 15, 2014Publication date: August 21, 2014Applicant: NOVARTIS AGInventors: David Jonathan GLASS, Mara FORNARO
-
Publication number: 20140235537Abstract: Compositions and formulations comprising N-glycosylated insulin analogues are described. In particular embodiments, the glycosylated insulin analogues are produced in vivo and comprise one or more the N-linked N-glycans selected from high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycans. In other embodiments, the N-glycan comprising the high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycan is attached to the insulin analogue in vitro. Examples of N-glycans include but are not limited to a molecule having a structure selected from N-glycans in the group consisting of Man(1—9)GlcNAc2; or selected from N-glycans in the group consisting of GlcNAc(1—4)Man3GlcNAc2; or selected from N-glycans in the group consisting of Gal(j.Type: ApplicationFiled: August 3, 2012Publication date: August 21, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Michael Meehl, Natarajan Sethuraman, Sandra Rios
-
Patent number: 8809501Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: GrantFiled: June 4, 2012Date of Patent: August 19, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20140228289Abstract: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).Type: ApplicationFiled: September 19, 2013Publication date: August 14, 2014Applicant: WYETH LLCInventors: Neil M. Wolfman, Soo Peang Khor, Kathleen N. Tomkinson
-
Publication number: 20140228282Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.Type: ApplicationFiled: April 23, 2014Publication date: August 14, 2014Applicant: Eli Lilly and CompanyInventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
-
Patent number: 8802102Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: January 3, 2014Date of Patent: August 12, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8802100Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: November 27, 2013Date of Patent: August 12, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8802101Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: November 27, 2013Date of Patent: August 12, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Publication number: 20140220046Abstract: Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.Type: ApplicationFiled: January 15, 2014Publication date: August 7, 2014Applicant: LIPOXEN TECHNOLOGIES LIMITEDInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
-
Patent number: 8796206Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.Type: GrantFiled: November 13, 2008Date of Patent: August 5, 2014Assignee: Amgen Inc.Inventors: Christopher James Sloey, Jason Ko, Tiansheng Li
-
Patent number: 8795670Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: November 27, 2013Date of Patent: August 5, 2014Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Publication number: 20140212952Abstract: Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhGDF-5 protein. Methods for isolating recombinant GDF-5 protein from an inclusion body of a cell are disclosed herein. The methods as disclosed are cost-effective, time-saving and are of manufacturing quality.Type: ApplicationFiled: January 25, 2013Publication date: July 31, 2014Applicant: Warsaw Orthopedic, Inc.Inventors: David S. Scher, Roger E. Harrington
-
Publication number: 20140213776Abstract: Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhGDF-5 protein. Methods for production and high expression of rhGDF-5 protein are disclosed herein. The methods of enhancing production and protein expression of rhGDF-5 protein as disclosed are cost-effective, time-saving and are of manufacturing quality.Type: ApplicationFiled: January 25, 2013Publication date: July 31, 2014Applicant: Warsaw Orthopedic, Inc.Inventors: David S. Scher, Roger E. Harrington
-
Publication number: 20140213511Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: January 27, 2014Publication date: July 31, 2014Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
-
Publication number: 20140212472Abstract: Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, LVKGRamide, derived from the C-terminus of Glucagon-Like Peptide 1 (GLP-1).Type: ApplicationFiled: July 5, 2012Publication date: July 31, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Joel F. Habener, Eva Tomas-Falco